Physician

Charles Sweeney, MD

According to 2025 Medicare claims, Charles Sweeney, MD (NPI: 1063414944) practices nephrology in the Rockford, IL market, with the plurality of this provider's patient population coming from Winnebago, IL. This provider's primary affiliated billing organization is RNA OF ROCKFORD, PLLC (NPI: 1336326388; TIN: 26-1497110) and primary practice location at 61107-5089. Sweeney is affiliated with the IRCCO (ACO ID: A2619) and OSF Healthcare System (ACO ID: A3289), participating under the MSSP model.

Sweeney's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,105 traditional Medicare patients, billed 5,613 HCPCS/CPT codes, and received $379,835 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,936 prescription claims across 577 beneficiaries totaling $255,791 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 42 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $367,929 and ending at $379,835. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $509,334 to $255,791. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,049	12,440	$367,929
2016	1,078	13,243	$426,877
2017	1,147	9,853	$310,811
2018	1,139	7,993	$415,195
2019	1,112	5,830	$364,397
2020	1,330	6,466	$483,400
2021	1,210	4,301	$342,656
2022	1,030	3,689	$294,733
2023	1,111	4,107	$303,883
2024	1,105	5,613	$379,835

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	351	2,351	$509,334
2016	350	2,205	$387,560
2017	389	2,665	$481,233
2018	419	2,662	$281,003
2019	387	2,021	$210,842
2020	376	1,958	$170,354
2021	397	1,791	$112,333
2022	430	1,957	$118,186
2023	495	2,414	$205,658
2024	577	2,936	$255,791

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	42	$560

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	493	648	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	326	406	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	206	425	$63
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	193	1,179	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	665	1,039	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	175	7,142	$133,168
Sevelamer Carbonate	Sevelamer Carbonate	34	2,215	$21,509
Jardiance	Empagliflozin	31	900	$17,000
Calcitriol	Calcitriol	762	52,672	$9,545
Cinacalcet Hcl	Cinacalcet Hcl	34	2,212	$6,625

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$201
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$188
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	17	$171

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Charles Sweeney, MD?

Tedicare shows public-source Medicare data for Charles Sweeney, MD (NPI 1063414944), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Sweeney, MD have ACO affiliation data?

Charles Sweeney, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and OSF Healthcare System (MSSP, ACO ID A3289).

What billing organization is linked to Charles Sweeney, MD?

Charles Sweeney, MD is linked to RNA OF ROCKFORD, PLLC (billing NPI 1336326388) in the available physician profile data.

Does Charles Sweeney, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.